Marc Schmitz (Institute of Immunology, Dresden, Germany) evaluated the immune architecture in another urologic tumor, renal cell carcinoma (RCC), focusing on monocytes expressing the 6-sulfo LacNAc (slan) modification of PSGL1, shortly termed slanMo. Here, SELPLG is linked to renal cell carcinoma.